Hesai Group American Depositary Share each ADS represents one Class B ordinary share (HSAI)
Fast GrowerFairStock Score: 39/100 — MIXED
Key Financials
| Current Price | $22.44 |
| Market Cap | $3.3B |
| P/E Ratio | 46.75 |
| ROE | 7.15% |
| Dividend Yield | —% |
| Sector | Consumer Cyclical |
Strengths
- Conservative balance sheet with debt-to-equity of just 0.09, providing financial flexibility
- Revenue growth of 47.5% demonstrates strong top-line momentum
Concerns
- Elevated P/E of 47.7x prices in substantial future growth that may not materialize
- Altman Z-Score of 1.5 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
Hesai Group American Depositary Share each ADS represents one Class B ordinary share is a small-cap consumer cyclical company valued at $3.3 billion. The business generates $3.0 billion in annual revenue with a 5.1% net margin. From a quality standpoint, Hesai shows distressed Altman Z-Score of 1.5 warrants caution and modest 7% ROE. On valuation, the stock is commanding a steep 47.7x multiple, with a modest 12% margin of safety vs Graham Number. Growth dynamics show revenue growing at 47.5% and profit growth of 464.1%. Our composite FairStock Score of 39/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Hesai's 47% revenue growth trajectory could accelerate as it captures additional market share in the consumer cyclical sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
At 48x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer